252 related articles for article (PubMed ID: 17579621)
21. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia.
Morabito F; Callea I; Console G; Stelitano C; Sculli G; Filangeri M; Oliva B; Musolino C; Iacopino P; Brugiatelli M
Haematologica; 1997; 82(5):560-5. PubMed ID: 9407721
[TBL] [Abstract][Full Text] [Related]
22. Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
Bulgar AD; Snell M; Donze JR; Kirkland EB; Li L; Yang S; Xu Y; Gerson SL; Liu L
Leukemia; 2010 Oct; 24(10):1795-9. PubMed ID: 20811400
[No Abstract] [Full Text] [Related]
23. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
24. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.
Campàs C; Cosialls AM; Barragán M; Iglesias-Serret D; Santidrián AF; Coll-Mulet L; de Frias M; Domingo A; Pons G; Gil J
Exp Hematol; 2006 Dec; 34(12):1663-9. PubMed ID: 17157163
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Moufarij MA; Sampath D; Keating MJ; Plunkett W
Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
[TBL] [Abstract][Full Text] [Related]
28. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Yamauchi T; Nowak BJ; Keating MJ; Plunkett W
Clin Cancer Res; 2001 Nov; 7(11):3580-9. PubMed ID: 11705880
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes.
Takagi K; Kawai Y; Yamauchi T; Ueda T
Biochem Pharmacol; 2004 Nov; 68(9):1757-66. PubMed ID: 15450941
[TBL] [Abstract][Full Text] [Related]
30. R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
Lindhagen E; Nissle S; Leoni L; Elliott G; Chao Q; Larsson R; Aleskog A
Cancer Chemother Pharmacol; 2007 Sep; 60(4):545-53. PubMed ID: 17186240
[TBL] [Abstract][Full Text] [Related]
31. Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin.
Wilson PK; Mulligan SP; Christopherson RI
Leuk Res; 2004 Jul; 28(7):725-31. PubMed ID: 15158094
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
[TBL] [Abstract][Full Text] [Related]
33. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair.
Yang LY; Li L; Keating MJ; Plunkett W
Mol Pharmacol; 1995 May; 47(5):1072-9. PubMed ID: 7746274
[TBL] [Abstract][Full Text] [Related]
34. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
[TBL] [Abstract][Full Text] [Related]
35. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
36. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
[TBL] [Abstract][Full Text] [Related]
37. Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.
Fong D; Kaiser A; Spizzo G; Gastl G; Tzankov A
Br J Haematol; 2005 Apr; 129(2):199-205. PubMed ID: 15813847
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
[TBL] [Abstract][Full Text] [Related]
39. [Molecular biology examination in chronic lymphocytic leukemia].
Telek B; Rejtó L; Mezei G; Karászi E; Kappelmayer J; Balázs M; Kiss A; Ujj G; Rák K; Udvardy M
Orv Hetil; 2001 Apr; 142(16):833-7. PubMed ID: 11340945
[TBL] [Abstract][Full Text] [Related]
40. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]